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Abstract 
 
Background: HIV leads to a high proportion of infectious disease morbidity and mortality among men who have 
sex with men (MSM) in Guatemala, yet prevention efforts like condom promotion and sexual health education in the 
country have failed to curb rates of infection among such populations. With the advent of pre-exposure prophylaxis 
(PrEP), new intervention strategies are possible. In 2015, the World Health Organization recommended that PrEP be 
included in HIV prevention strategies for all high-risk groups worldwide. However, to date, no studies have 
evaluated PrEP implementation at a community-based level in Guatemala.  
Purpose: In this study, we seek to identify the perceived opportunities, challenges and implementation strategies 
among key stakeholders regarding PrEP as an HIV prevention tool in Guatemala City.  
Methods: We conducted qualitative in-depth interviews with key informants, including community-based 
organization leaders, international donors, Ministry of Health representatives, and medical providers.  
Results: We found that while knowledge of PrEP is high, a large portion of respondents desire more research 
specific to Guatemalan MSM. Additionally, we found that the large majority of perceived barriers to PrEP 
implementation are political and sociocultural including lack of sustainability, lack of political advocates, and a 
hostile political and social environment toward LGBT people. We identified community-based organizations to be 
perceived as uniquely situated in Guatemala to implement a PrEP strategy given their ample social networks, user 
and community trust, and capacity to reach, recruit, retain, and follow-up with patients taking PrEP. Such peer-to-
peer strategies were seen as essential to any HIV prevention strategy by many participants in our study. 
Additionally, the promotion of PrEP for serodiscordant partners may provide a gateway to amplifying the use of 
PrEP and emphasizing its urgency in Guatemala. 
Conclusion: While Guatemala poses unique challenges to implementing PrEP, the barriers are not too great to 
prevent the initiation of PrEP in the country. A PrEP strategy may currently be feasible with the proper guidance and 
support of qualified providers and organizations with technical and financial support from international donors. Such 
a strategy should be coupled with policy change to protect vulnerable groups like MSM and with utilization of 
extant resources in an intentional, efficient, and professional manner.  
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Introduction 
 
Since the early 1980s, HIV has been devastating communities worldwide leading to 
millions of deaths each year. Although numerous efforts to halt the epidemic such as condom use 
and sexual health education have been promoted globally, several population subgroups continue 
to suffer from infection and HIV-related complications despite the advance of novel 
antiretroviral regimens.
4
 In particular, men who have sex with men (MSM) and transwomen 
often face institutional barriers, discrimination, and health system exclusion making them more 
vulnerable to HIV infection, morbidity, and mortality.
30
  
Until recently, HIV prevention strategies have focused primarily on consistent and 
correct condom use, sexual health education, treatment of sexually transmitted infections, and 
treatment of HIV-positive persons as prevention. Unfortunately, for MSM and transwomen in 
many low and middle income countries, these strategies, while helpful, have not been enough to 
stop the epidemic. Vulnerable populations, like these, continue to be exposed to and suffer 
greatly from HIV.  
An innovative strategy for prevention known as pre-exposure prophylaxis (PrEP) which 
involves antiretroviral treatment for HIV-negative persons has emerged in the past several years 
with great promise to curb HIV infections among HIV-negative people. Much of the research, 
however, regarding PrEP has been done in a first-world context, ignoring the unique challenges 
that many low/middle-income countries, often with the world’s most vulnerable populations, 
may face.
5-13
 This paper aims to describe the Guatemalan context surrounding a PrEP strategy 
for MSM, emphasizing the perceived barriers and facilitators as revealed through key informant 
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in-depth interviews, and making recommendations for such a strategy to be employed in the 
country. 
Background 
 
HIV and Guatemala 
 
Guatemala is a low/middle-income country and the largest in Central America, with a total 
population of around 15,000,000.
1 
Currently, HIV/AIDS ranks 9
th
 among causes of death and 2
nd
 
in infectious disease causes of death in the country, following lower respiratory infections.
1
 
While 53,000 Guatemalans were living with HIV in 2014, with an adult prevalence of 0.5%, the 
epidemic disproportionately affects specific subpopulations.
1
 
 The HIV epidemic in Guatemala is considered a concentrated one, affecting primarily 
men who have sex with men (MSM) and transwomen.
2,3
 Several studies from 2003 to 2013 have 
estimated the prevalence of HIV among MSM to range between 8.9% and 18.3% in the capital.
4
 
MSM also account for nearly 58% of AIDS cases in the country.
4 
Among transwomen, 
prevalence of HIV may be even higher, approaching 23.8% or one in four transwomen.
4
 
 
Although HIV prevention efforts have sought to target these specific populations, they 
have largely failed to curb the rates of infection or to improve behaviors related to HIV 
prevention. Only 63.3% of MSM report having used a condom during last anal intercourse with a 
male partner and only 44.8% had received an HIV test in the last 12 months and is aware of the 
result.
4
 Only 57% of MSM have participated in an HIV prevention program.
4
 It is possible that 
many of these numbers may underestimate the prevalence of HIV and high-risk behaviors among 
MSM since much of the extant HIV research captures more readily accessible MSM through 
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time-location sampling, neglecting hidden subpopulations that may have higher infection 
rates.
15,16 
In Guatemala, HIV is not evenly distributed geographically either; rather it concentrates 
in large urban areas of the country including the capital and surrounding townships. In 2013, 
18.12% of new cases of HIV in the country occurred in Guatemala City, the highest of all 22 
departmental divisions.
4
  
Pre-exposure Prophylaxis (PrEP) 
 
Pre-exposure prophylaxis, also known as PrEP, is biomedical intervention against HIV in 
which HIV-negative people take antiretroviral medications (Tenofovir+Emtricitabine) to avoid 
contracting the infection. While this regimen has been used in conjunction with other 
antiretrovirals for years in triple-therapy to treat HIV-positive individuals, it was not until 2010 
that researchers first documented its effectiveness at preventing HIV infection when used 
prophylactically.
5
 Since that time, it has been demonstrated to reduce the risk of HIV infection 
through sexual contact in gay and bisexual men, transgender women, and heterosexual men and 
women as well as in persons that inject drugs.
6-8
  
HIV negative people who take one pill daily can prevent HIV infection with 96 to 100 
percent effectiveness by preventing HIV from being able to copy itself in the body after being 
exposed.
9
 PrEP is not a cure for HIV and must be taken daily for 7 days before it begins to 
provide protection against HIV in men.
10
 PrEP does not prevent other sexually transmitted 
infections (STIs) so it is important to use other methods of STI prevention like condoms.
11
The 
most common side effect is nausea or gastrointestinal upset. In rare cases side effects can include 
kidney damage and renal failure.
12
 It is recommended that blood tests for kidney function and 
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sexually transmitted infections are performed every 3 to 6 months on persons who are taking 
PrEP.
13
 
In October 2015, after various international publications documented the reproducibility 
of PrEP efficacy among MSM, the World Health Organization (WHO) recommended including 
PrEP as part of HIV prevention strategies worldwide for vulnerable populations which include 
MSM, transgender women and female sex workers.
14
 
Purpose of Study 
 
Given the concentrated geographic and demographic nature of the HIV epidemic in 
Guatemala which classifies MSM as a vulnerable population according to the WHO and given 
the biomedical effectiveness of PrEP, it may be a plausible and timely tool to be incorporated 
into HIV prevention efforts in the country. However, to date, no study has evaluated the specific 
Guatemalan context of a potential PrEP strategy. Our research team, in conjunction with one of 
the largest HIV prevention organizations in Guatemala with a focus on MSM, Colectivo Amigos 
contra el Sida (CAS), sought to improve understanding of the context surrounding PrEP for 
MSM in Guatemala. The purpose of this study was to identify stakeholders’ perceptions of 
barriers and facilitators to a pre-exposure prophylaxis strategy among MSM in Guatemala City 
with the aim to analyze the current climate around PrEP and to propose policy adjustments that 
could promote such a strategy.  
Literature Review 
 
Prior to the initiation of our study, a brief literature review on HIV prevention among 
MSM in Guatemala was conducted via PubMed. We used the MeSH Terms “HIV and 
prevention and MSM and Guatemala” or:  
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("hiv"[MeSH Terms] OR "hiv"[All Fields]) AND ("prevention and control"[Subheading] 
OR ("prevention"[All Fields] AND "control"[All Fields]) OR "prevention and 
control"[All Fields] OR "prevention"[All Fields]) AND ("Mens Sana Monogr"[Journal] 
OR "msm"[All Fields] OR "Mater Sociomed"[Journal] OR "msm"[All Fields]) AND 
("guatemala"[MeSH Terms] OR "guatemala"[All Fields]) 
This algorithm returned 10 initial articles. Of these, 7 met the following inclusion criteria (SEE 
APPENDIX A)
15-21
: 
 Articles must be written in Spanish or English 
 Population studied must be partially or completely from Guatemala. If partial, analysis 
must separate out findings for Guatemala.  
 Articles must be related to HIV and prevention 
 Articles must specifically study MSM 
Based on our review of the literature, we determined that little is known about HIV prevention in 
Guatemala among MSM. Only 6 unique articles were found. Of those, only one evaluated an 
intervention strategy.
21
 Other articles documented the social networks and themes for 
intervention and methods strategies to be incorporated in prevention efforts.
16-17,20
 Other 
publications identified the sociobehavioral dynamics of MSM in Guatemala and risk factors for 
HIV like violence.
15,19
 One article highlighted the incidence and prevalence of HIV and STIs in 
Guatemala compared to other Central American countries, yet much of the research is 
outdated.
15,
 
 
Methods 
 
In order to identify stakeholder perceptions of the facilitators and barriers to a PrEP 
strategy in Guatemala City, we determined in-depth interviews with key informants and content 
analysis of their responses to be the most appropriate and efficient means of capturing a 
complete picture of the Guatemalan context surrounding PrEP. We outline our methods below.  
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Interviewer 
 
I am the interviewer and primary investigator of this study. I am an MD/MPH candidate 
at the UNC School of Medicine and UNC Gillings School of Public Health with a Graduate 
Certificate in LGBT Health from George Washington University and a Bachelor’s in Spanish 
and Medicine, Health and Society from Vanderbilt University. My primary interests include 
LGBT health, Latino health, and family and preventive medicine. This is my first qualitative 
research endeavor involving in-depth key informant interviews with policy recommendations 
based on the results, and it is my first time as primary investigator. My advisors included Dr. 
Clare Barrington and Dr. Sue Tolleson-Rinehart, both faculty professors at the Gillings School of 
Public Health; Dr. Tolleson-Rinehart’s primary faculty appointment is in the Department of 
Pediatrics in the School of Medicine.  Dr. Tolleson-Rinehart also provided me with training in 
research designs appropriate to this kind of study the semester prior to the research project. I 
received a one time, $3000 Perkins-Burke Fellowship to cover the costs of travel, lodging, and 
transportation in the country. 
I had previously participated in public health work in Guatemala in collaboration with the 
Universidad del Valle, a private university in the capital, and their HIV Research unit. I thus had 
several contacts in Guatemala prior to the start of the study. Of the 18 participants interviewed, I 
had previously met 5 of them. One had been a former co-worker at the HIV and STI Surveillance 
Office. I was introduced to the other interview respondents via an official letter from UNC from 
Dr. Clare Barrington and again at the time of interview. Participants were informed that the 
interviewer was an MD/MPH candidate conducting key informant interviews about PrEP as part 
 7 
 
of his Master’s Project at the University of North Carolina whose results would then be written 
up in this Master’s Paper.  
 
Key Informant Selection Criteria 
 
We considered key informants to be less vulnerable than key population members given their 
positions of leadership and to be most knowledgeable on HIV prevention and PrEP strategies for 
MSM in Guatemala. In order to be considered a key informant or elite stakeholder, potential 
respondents had to meet the following criteria: 
 Participants had to work in some capacity along the HIV prevention  cascade (See Figure 
1).
22,23
 
 Participants had to be in positions of leadership within non-profit organizations, medical 
clinics, or governmental entities at the time of the interview. 
 Participants had to be based in Guatemala City. 
 Participants had to work directly or indirectly with key populations specifically including 
MSM. 
Together with Colectivo Amigos contra el SIDA, one of the largest HIV prevention 
organizations for MSM in Guatemala, we identified 27 potential elite stakeholders who met our 
inclusion criteria. This list was cross-referenced with the Centers for Disease Control list of HIV 
prevention entities in Guatemala. Of those, 24 were contacted via telephone or email with 18 
responding with agreement to participate in our study (SEE APPENDIX D). The three 
organizations that were not contacted either primarily work with transgender populations or had 
overlap with other organizations already contacted. In this way, by recruiting broadly, we aimed 
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to reach data saturation in which only recurrent themes rather than new themes would arise by 
the end of interview collection.
31
  
Prior to any contact with possible interview respondents, we submitted this study to the UNC 
Institutional Review Board, who ruled the work “Not Human Subjects Research” because of the 
nature of the policy questions we were asking (IRB No. 16-0535) 
Figure 124 
Fhi360. Project: Linkages across the Continuum of HIV Services for Key Populations Affected by HIV 
(LINKAGES). Fhi360 2014.  
 
Instrument Development and Translation 
 I developed the interview instruments based on previous and similar interview design in 
Guatemala and other low/middle income countries. The instrument consisted of 25 questions 
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across six categories including General Information, HIV Prevention, PrEP, PrEP Management, 
PrEP Retention and Adherence, and further prevention needs (SEE APPENDIX B).  
 Because all interviews were to be conducted in Spanish, I followed best-practice 
translation procedures.
25,26
 This involved translation from the original English version to Spanish 
by me; I am a certified medical Spanish interpreter. The subsequent original Spanish translation 
was then back-translated to English by an independent and local physician and director of the 
Latino Health Selective at UNC School of Medicine. That second English version was then 
translated again to Spanish by a third independent translator who is a Guatemalan native and 
manager at a bilingual call center. We carefully selected the final translator as a Guatemalan with 
the hope of reducing dialect and comprehension issues at the time of interview. The three 
versions were cross-referenced for content differences, which were found to be minimal. 
Corrections were made in any grammar or vocabulary differences to capture the intent of each 
question. This final version was then reviewed by CAS as an extra step to guarantee 
comprehension and fluidity (SEE APPENDIX B). The interview instrument was not pilot tested. 
Interviews 
 
 I conducted all interviews face-to-face in the location of the participant’s choosing. In 
most cases, interviews took place in the workplace of the participant or in a separate quiet venue 
that they selected. Interviews ranged from 30 to 90 minutes and were audio recorded. 
Participants were read a statement of confidentiality prior to initiation of the interview. 
Interviews were conducted in Spanish for all but one interviewee whose native language was 
English. I took hand-written notes during the interview itself. No repeat interviews were 
performed. Following each interview, I made typed field notes from the handwritten notes and 
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filled out a detailed “Key Informant Analysis” summarizing the main themes highlighted in each 
interview (SEE APPENDIX C).  
Additionally, following the interviews the audio recordings were given to one of two paid 
transcriptionists who were part of the research team. Two to three transcriptions were received 
from each transcriptionist each week with all transcriptions received by June 21, 2016. These 
transcriptionists had previously worked with Dr. Clare Barrington on other research projects in 
Guatemala and are Guatemalan natives. Transcripts were not returned to participants. 
Preliminary Analysis 
  
From the “Key Informant Interview Analysis” documents that summarized the main 
findings of each individual interview, I noted independent themes and placed them into an Excel 
spreadsheet with every subsequent interview being cross-referenced for similar themes. It is from 
this preliminary analysis of the data rather than coding of full transcripts that the results in this 
paper are drawn. 
Data Analysis 
 
 Official coding of interview transcripts will take place in the coming months by the 
research team consisting of three coders including the primary investigator, Dr. Clare Barrington 
of the Gillings School of Public Health, and doctoral candidate Dirk Davis. The coders will 
derive themes from the data and support them with participant quotations. Atlas.ti will be used to 
assist with coding. Research findings will be shared with key informants although they will not 
be asked to provide feedback on the findings. 
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Data Triangulation 
  In our study, we aimed to triangulate our findings in several ways. Data triangulation is 
the attempt to isolate the most correct answer to a research question using different data sources 
and methods.
27
 Several types of triangulation exist including data triangulation, investigator 
triangulation, theory triangulation, and methodological triangulation.
27,28
 In our study, we sought 
to triangulate across several of these spheres. We included data triangulation within our research 
design by performing in-depth interviews across different organization types (SEE APPENDIX 
D). The organizations our participants represent include community-based organizations, 
international HIV/AIDS funders and organizations, medical clinics, and the Guatemalan Ministry 
of Health. Conducting the limited systematic literature review previously mentioned, in 
conjunction with the in-depth interview findings, also enabled us to triangulate our methods. 
Finally, including three coders for the coding and analysis phase of our study will ensure 
investigator triangulation. Triangulation will engender a more complete and accurate picture of 
the context surrounding PrEP in Guatemala, rather than depending solely on one investigator, 
type of organization, or method.  
Results 
 
As mentioned above, the results in this paper are taken from a preliminary review of “Key 
Informant Interview Analysis” thematic cross-referencing rather than from coded transcripts.  
PrEP Knowledge 
 
 All participants were asked about their baseline knowledge of PrEP. Eighty-nine percent 
of participants agreed that PrEP was bio-medically effective at preventing HIV. Thirty-three 
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percent referenced the 2015 WHO recommendations about PrEP inclusion in HIV prevention 
efforts for vulnerable populations. Thirty-nine percent cited the need for a specific and well-
defined patient profile that identifies patients that can take PrEP. And 39% cited the need for 
more research among key populations in Guatemala including MSM, transwomen, and female 
sex workers. Thus, it appears that accurate information about PrEP and the best PrEP practices 
has been disseminated widely across HIV prevention organizations. However, many respondents 
still have unanswered questions that they would like to see addressed through PrEP research in a 
Guatemalan context. 
Barriers to PrEP Implementation 
 
 We divided the barriers to implementation along a socioecological framework of health 
and HIV prevention which included political, community, interpersonal, and individual 
barriers.
22
  
 Respondents recognized a number of political barriers: 78% percent of participants 
reported a lack of government resources or sustainability as an important barrier to a national 
PrEP implementation strategy. In addition, 72% percent emphasized a hostile political climate 
towards LGBT people that would make it difficult to garner political support for a PrEP strategy. 
A lack of healthcare infrastructure to support a PrEP strategy was cited by 33% of participants. 
Twenty-eight percent reported a lack of Ministry of Health leadership to guide a PrEP strategy in 
Guatemala.  
 In terms of community barriers, 39% of participants highlighted the perception that HIV-
positive patients in Guatemala already have difficulty accessing antiretroviral (ARV) treatment, 
which would serve as a barrier to using ARVs as prevention because of the need to shift already 
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scarce medications to an otherwise healthy population. However, opinions differed especially 
across international HIV/AIDS funders, as several emphasized that no “stock-outs” of ARVs 
have occurred in Guatemala to date even though the government has limited access to them.  
 Community-based organizations (CBOs) disagree about the need, usefulness, and 
viability of a PrEP strategy for their users. Seventy-eight percent of participants mentioned some 
level of MSM and transgender organizational resistance to PrEP in Guatemala. While some 
organizations want PrEP, others are strongly opposed, leading to a decreased demand and 
minimized voice for PrEP. Much of this resistance was attributed by PrEP-supportive key 
informants to misinformation about PrEP among key populations.  
 In terms of individual barriers, 44% of participants reported that side effects could be a 
potential barrier to PrEP implementation. Additionally, 44% identified individual patient costs as 
barriers to PrEP access. Fifty percent cited individual and healthcare-related stigma and 
discrimination against MSM and transwomen, including a lack of differentiated care services, as 
barriers to a PrEP implementation strategy. Perceived fear of decreased condom use resulting in 
increased sexually transmitted infections was mentioned by 28% of participants as a moral 
barrier to giving PrEP to MSM. Fifty percent reported fears of poor adherence among MSM 
leading to resistant HIV-strains as a barrier to PrEP acceptance in Guatemala, and, finally, 44% 
indicated a lack of knowledge on the part of individual MSM about PrEP which could be a 
barrier.  
 Other potential barriers, mentioned by respondents included policies that prevent the 
generic form of PrEP from coming to Guatemala, lack of CBO professionalism in service 
provision, resistance to the medicalization of prevention, disruption of the sex-worker economy, 
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cultural barriers against taking medications, and the idea that PrEP is elitist and bolsters 
machismo and patriarchy by given in to the idea that males who do not want to use condoms 
should be catered to. 
 
Facilitators to PrEP Implementation 
 
 Participants identified several existing factors and several potential factors in Guatemala 
that could facilitate PrEP acceptance and implementation. Fifty-six percent of participants, the 
majority of which were international donors and CBOs themselves, noted that CBOs are 
uniquely situated in Guatemala to be essential to a PrEP implementation strategy given their 
community trust, social networks, and capacity to distribute PrEP information, PrEP-related 
services, and PrEP itself.  Fifty percent also mentioned that CBOs should lobby for PrEP and put 
pressure on the Ministry of Health to promote PrEP and to partner with CBOs in its 
implementation.  
In terms of PrEP promotion strategies, 44% of participants view serodiscordant couples 
as a gateway to bringing PrEP into Guatemala and as an urgent subgroup among MSM who 
could most benefit from PrEP. Furthermore, 28% believed that PrEP should be framed as a 
human right, in which every person has the right to choose to take control of his or her own 
health; “PrEP should be another option under the fan of prevention strategies”. Finally, 
participants mentioned that more research (50%) and a future PrEP information campaign (44%) 
could aid in further acceptance and feasibility of PrEP implementation. Other mentions included 
the importance of strict medical supervision, normalization of PrEP use, and improving the 
health care infrastructure. 
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One interesting model for PrEP that was emphasized by several participants was a 
medical scheme in which key populations are tested for HIV, and if positive are tied to ARV 
treatment and follow-up, and if negative are linked to PrEP counseling, initiation, and follow-up. 
PrEP Management 
 
 Participants were also asked about the ideal conditions of PrEP distribution, frequency of 
pick-up, and complementary services. Sixty-seven percent of participants stated that PrEP should 
be distributed to key populations through CBOs; 39% emphasized the use of pre-existing HIV 
clinics in the country. Only 11% of participants thought that pharmacy distribution of PrEP was 
the best strategy in Guatemala. Thirty-three percent recommended individualized schedules for 
PrEP pick-up depending on the needs of the patient. Forty-four percent recommended pick-up 
every three months.  
 In terms of additional services, 50% of participants recommended that PrEP be tied to 
comprehensive medical care. Seventy-two percent emphasized the need for routine lab work 
including screening and treatment of sexual transmitted infections. Other services mentioned 
included educational information, referrals, nutrition counseling, mental health care, and HPV 
vaccination.  
 
Barriers to Retention and Adherence 
 
 Apart from barriers to PrEP implementation, participants commented on the barriers to 
retention and adherence of MSM patients in a PrEP program. Again, these fell into a 
socioecological model of prevention.
29
 In terms of political and societal barriers 72% percent of 
participants emphasized that trans- and homophobia leading to stigma and discrimination against 
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key populations would be barriers to PrEP retention and adherence. Fifty-six percent thought that 
lack of differentiated care for MSM or transgender patients would also be a barrier. Other policy 
barriers included lack of protective policies for key populations, poor provision and quality of 
health care and mental health care services, and lack of protection from breaches of 
confidentiality.  
In terms of individual barriers to retention and adherence, 39% percent of participants 
mentioned cost for the patient as a barrier. Lack of information or education about the 
medication and its use were also cited by 39% of participants. Seventy-two percent of informants 
emphasized the importance of psychosocial context referencing interpersonal violence, drugs and 
alcohol use, and unstable employment as external factors that could influence retention and 
adherence in a PrEP program. Other barriers included poor self-esteem, time, and lack of ability 
and space for key populations to self-identify. 
  Cultural norms in Guatemala transcending all levels of the socioecological model 
including a culture of abandonment, religion, male aversion to seeking medical care, a non-
preventive health care culture, and stigma and discrimination against taking medications were 
also seen as important barriers by 44% of participants. 
Facilitators to Retention and Adherence 
 
 In the final section of the interview, participants were asked to discuss the facilitators to 
retention and adherence in a PrEP program among MSM. Fifty-six percent highlighted the 
previous successes and importance of peer-to-peer work which involves strategies for key 
populations developed by key populations and implemented by key populations. Such strategies 
were cited by several participants as effective at improving retention and adherence to ARVs by 
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HIV-positive patients. Fifty percent of participants also mentioned the importance of using 
existing HIV clinics and MSM-specific clinics that already have the technical support, 
professional services, and trust of the community, to improve PrEP retention and adherence. 
Twenty-eight percent mentioned the importance of willpower and the idea that MSM who want 
to take PrEP will be responsible to take it. Another interesting proposal by several participants 
involved the use of mobile technology including text messages with health information, 
appointment reminders, and alarms to take their medication, which have been successful in 
improving ARV treatment of HIV.  
 Other promoters of retention and adherence identified by our respondents included self-
help groups, adherence courses, mental health care services, CBO trust and social networks, pill 
counting, guarantees of confidentiality, and close follow-up.  
 
Discussion 
 
 This study identified the perceived facilitators and barriers among key informants to a 
PrEP strategy in Guatemala among MSM, providing a more complete snapshot of the current 
sociocultural context around this intervention in the country.   
 While the large majority of participants know that PrEP is biomedically effective and 
while many are familiar with the 2015 World Health Organization recommendations, doubts 
about the viability of PrEP in Guatemala have led to resistance until further research among key 
populations is done nationally. Even participants who support a PrEP strategy highlight the need 
to identify the correct patient profile for PrEP in a Guatemalan context.  Although many key 
informants have received accurate information about PrEP, it appears that continued 
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misinformation and unwarranted misconceptions about the potential for side effects remain 
barriers, especially among CBOs that are in opposition to PrEP.  
 One of the largest barriers to PrEP in the country is political. Lack of government 
funding, poor health care infrastructure, lack of sustainability and lack of Ministry of Health 
responsibility for a PrEP strategy are cited often by key stakeholders as hurdles to 
implementation of a national PrEP program and to adherence and retention in such. Part of the 
problem appears to be a hostile political environment against LGBT people. Given the largely 
conservative and religious climate in Guatemala, stigma and discrimination make discussing 
alternative forms of sex and sexuality and policies to protect sexual minorities difficult. This 
same stigma and discrimination could hinder retention and adherence in a PrEP program.  
Additionally, because of lack of leadership and the high turnover rates of government employees 
in Guatemala, there are no current government advocates for PrEP who could help to promote 
favorable policies for key populations. Without such advocates or lobbyists, implementing PrEP 
from a governmental level will be difficult.  If advocacy is to take place, the burden largely falls 
on CBOs; however, advocacy on the part of CBOs is weakened by the ideological divisions 
among them and the lack of a unified demand for PrEP.  
 The individual barriers to PrEP referenced by elite informants such as fears about side 
effects, patient costs, poor adherence among MSM, decreased condom use, and increased 
sexually transmitted infections could be ameliorated with improved information about PrEP and 
policies that promote differentiated care services where patients feel safe, are able to self-
identify, have confidential treatment, and trust providers such that they are closely tied to 
professional and comprehensive medical care with regular follow-up. Such differentiated care 
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services do exist at some CBOs like CAS, as well as at some existing HIV clinics in the capital, 
but they need continued financial and technical support for a PrEP strategy to work. 
 Additional barriers to individuals in terms of retention and adherence in a PrEP program 
include cost, lack of information, cultural norms about health and medication, and psychosocial 
context involving interpersonal violence, drugs and alcohol, and unstable employment. Many of 
these variables may have more to do with the lack of policies that protect LGBT individuals in 
Guatemala from employment, familial, and social discrimination and violence which make them 
vulnerable economically, educationally, physically, mentally, and socially than they do with any 
inherent part of being LGBT. These institutional and societal barriers lead to poorer mental 
health outcomes like depression and low self-esteem for these populations. 
 CBOs appear to be uniquely situated in Guatemala to implement a PrEP strategy given 
their ample social networks, user and community trust, and capacity to reach, recruit, retain, and 
follow-up with patients taking PrEP. Such peer-to-peer strategies were seen as essential to any 
HIV prevention strategy by many participants in our study. Ideally, CBO efforts could be 
bolstered by the Ministry of Health if they were willing to partner with the CBOs. Additionally, 
the promotion of PrEP for serodiscordant partners may provide a gateway to amplifying the use 
of PrEP and emphasizing its urgency in Guatemala.  
Conclusion 
 
Key informants perceive significant barriers to a PrEP implementation strategy for MSM 
in Guatemala especially if it is to be carried out on a governmental level. Policies are few in 
terms of protecting LGBT populations and promoting health for them, and the political climate 
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continues to be strongly opposed to LGBT people. If PrEP is to be implemented nationally and 
from the Ministry of Health, policies that recognize LGBT persons as vulnerable and provide for 
resources and health care specific to them will be needed. Policies directed at changing the 
psychosocial climate are warranted such as policies that penalize violence against LGBT 
persons, protect equal employment and educational opportunities for them, and prevent 
discrimination in the health care setting.  
However, given the time-consuming nature of policy change, if PrEP is to be 
implemented in a timely manner, there may be other nongovernmental avenues by which it can 
be done. CBOs are positioned favorably for PrEP implementation, and many international 
HIV/AIDS funders view CBOs as competent to distribute and manage PrEP among MSM in 
Guatemala without the need for government involvement. International organizations appear 
willing to provide financial and technical support to CBOs to begin including PrEP in their 
repertoire of HIV prevention strategies as long as proper protocols for identifying, recruiting, 
retaining, and following-up with patients are standardized. The vision would be that patients who 
test negative and who fit the correct patient profile are started on PrEP with consistent and 
comprehensive care in the same way that HIV-positive patients are immediately connected to 
antiretroviral treatment.  With partnerships between CBOs, medical providers, and international 
organizations, more research can be done specific to key populations like MSM in the country. 
However, while more research is desired and warranted, it does not appear that such research 
must preempt PrEP implementation.  
PrEP information distribution and promotion efforts should continue in Guatemala with 
CBOs taking a lead in educating key populations, stakeholders, and political actors. Two 
strategies of framing PrEP were suggested by key informants and offer promise. The first is 
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framing PrEP as a human rights issue in which every patient, every person, has the right to take 
control of his or her health and should be able to make an informed decision and have access to 
PrEP if so desired. The second is that serodiscordant couples should be prioritized as a way to 
increase PrEP use in the country, aiding in its normalization while also benefitting this 
vulnerable subgroup.  
In summary, while Guatemala poses unique challenges to implementing PrEP, the 
barriers are not too great to prevent the initiation of PrEP in the country. A PrEP strategy may 
currently be feasible with the proper guidance and support of qualified providers and 
organizations; that strategy should be coupled with policy change to protect vulnerable groups 
and with utilization of extant resources in an intentional, efficient, and professional manner.  
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Appendices 
 
Appendix A – Limited Systematic Review of the Literature 
 
HIV Prevention among MSM in Guatemala: A Limited Systematic Review 
Abstract 
 Little is known about HIV/AIDS prevention among MSM in low/middle income countries like 
Guatemala. In this systematic review we sought to uncover the current published research findings 
regarding HIV and prevention among MSM in Guatemala. We identified and summarized six articles 
produced by our search.  
Background 
 HIV/AIDS is the 9th leading cause of death in Guatemala and the second leading cause of 
infectious disease death.
1
 Although adult prevalence of HIV/AIDS is 0.5% nationally, it is estimated that 
among MSM prevalence ranges from 8.9% to as high as 18.3% especially in urban areas like Guatemala 
City.
2,3,4
 MSM also account for 58% of AIDS cases in the country.
4
 Prevention efforts in Guatemala 
among MSM have not been successful with only 63% of MSM having used a condom during last anal 
intercourse, only 57% having participated in an HIV prevention program, and only 44.8% having 
received an HIV test in the last 12 months and is aware of the result.
4
 Thus, this limited systematic review 
seeks to summarize the findings of the extant literature surrounding HIV prevention in Guatemala among 
MSM. 
Methods 
This limited systematic review followed standard systematic review procedures and sought to identify and 
summarize the current knowledge base regarding HIV prevention among Guatemalan MSM.   
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Literature Search 
 
I used PubMed to identify all published journal articles in Spanish or English related to the topic of 
interest. The search was not limited by start or end dates, and no authors were contacted. “Appendix A: 
Table 1” contains the MESH terms used as of May 3, 2016. At the time of the writing of this systematic 
review, results of the search remain the same.  
Selection Criteria 
 
Articles were selected for inclusion based on language, setting, population, and topic which is also 
documented in “ Appendix A: Table 2”. Articles and abstracts were reviewed by me, the primary 
investigator, for inclusion. If questions of inclusion arose, I included the article until the full text review 
stage. Included articles were submitted to full-text review as a final step. Of 10 articles on initial search, 7 
were included for review and 3 were excluded due to settings outside of Guatemala.
15-21
 One was a 
duplicate
18
; thus, 6 total articles were reviewed.  
Data Review 
 
I reviewed all articles and was the sole reviewer. The extracted information included description and 
principles of the study, type and nature of the research, the overall conclusions as related to HIV 
prevention, and the quality of the research. Quality was determined based on internal and external validity 
of each study and its relevance to HIV and prevention among MSM in Guatemala. 
Results 
Six articles were included in the final limited systematic review.
15-17,19-21
 “Appendix A: Table 3” 
summarizes the included articles including the investigator’s ranking of quality.  Articles were published 
between 2007 and 2014. Of the six articles reviewed 67% reported quantitative results with the other 33% 
reporting qualitative findings.  
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The quantitative studies identified several important aspects of the HIV prevention context in Guatemala. 
Soto et. al found that in spite of high HIV prevention knowledge, incorrect beliefs about transmission 
were also substantial, and HIV prevalence was high. Additionally, few MSM sought and received 
voluntary HIV test results. Condom use was also low.
15
 In terms of prevention research methods, Paz-
Bailey et. al underscored that respondent-driven sampling may uncover hidden members of key 
populations and may cost less than time-location sampling.
16
 Wheeler et. al found that MSM who 
experience physical and verbal violence are at increased risk of HIV and other sexually transmitted 
infections.
19
 Firestone et. al found that combination prevention strategies in Guatemala were higher in 
coverage compared to other Central American countries, although increased coverage and intensity is still 
warranted.
21
  
 The two qualitative studies also provided insight to key populations and their perspectives on 
HIV prevention. Rhodes et. al identified 20 sociocultural themes highlighted by key populations as 
important to include in prevention efforts for MSM.
17
 Tucker et. al underscored the importance of friends, 
sex clients, and family members in the social networks of MSM as support systems that bolster 
prevention strategies.
20
  
Discussion 
According to the literature, HIV and other STIs continue to negatively affect Guatemalan MSM at 
disproportionate rates compared to other subpopulations and compared to other Central American 
countries.
15
 Interpersonal violence also places Guatemalan MSM at high risk for HIV infection.
19
 
Prevention strategies should incorporate sociocultural themes that are relevant to Guatemalan MSM and 
may also benefit from respondent-driven sampling to identify hidden subgroups of MSM.
16,17
 Social 
networks may also be crucial support systems for preventing HIV among MSM in Guatemala.
20
 Finally, 
combination prevention therapy seems to show promise, but it lacks coverage and intensity in the county 
and should be scaled up.
21 
 28 
 
Strengths  
 
 The primary investigator followed PRISMA checklist in order to be as thorough as possible in this 
review. The inclusion criteria were limited which helped to identify the most relevant articles for the 
review.  
 Limitations  
 
This systematic review is limited in scope given the specific search and inclusion criteria employed. It is 
possible other HIV prevention-related research was missed under different MeSH terms. Given that only 
published studies were included, it is also possible that prevention interventions on a community level or 
those that have not been published were missed. Publication bias may limit understanding the complete 
picture regarding HIV prevention among MSM in Guatemala. Additionally, the quality ratings of the 
articles, based largely on the methods and sample sizes, have not been studied and are thus subjective 
from the perspective of the primary investigator.  
Conclusion 
Little research has been published about HIV prevention among MSM in Guatemala, and thus very few 
articles were found in our search. The literature does identify outdated HIV prevalence statistics and 
behavioral and social risk factors including violence. While much of the literature discusses strategies to 
include in prevention such as respondent-driven sampling, sociocultural themes, and social networks, 
only one assesses an HIV prevention intervention. Thus, more specific research contextualizing the HIV 
epidemic among MSM and the climate around intervention strategies is needed.  
Funding 
No funding was received for this review. 
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Table 1: Search Strategy 
 
 
 
PubMed 
“HIV and Prevention and MSM and 
Guatemala” 
("hiv"[MeSH Terms] OR "hiv"[All 
Fields]) AND ("prevention and 
control"[Subheading] OR 
("prevention"[All Fields] AND 
"control"[All Fields]) OR "prevention and 
control"[All Fields] OR "prevention"[All 
Fields]) AND ("Mens Sana 
Monogr"[Journal] OR "msm"[All Fields] 
OR "Mater Sociomed"[Journal] OR 
"msm"[All Fields]) AND 
("guatemala"[MeSH Terms] OR 
"guatemala"[All Fields]) 
 
 
 
 
Table 2: Eligibility Criteria 
Language Articles had to be written and published in Spanish or English. 
Setting Articles had to have a study setting that partially or fully included 
Guatemala. Study results had to include specific findings for 
Guatemala.  
Population subgroup Articles needed to focus in part or fully on men who have sex with men 
(MSM). Articles that covered other populations needed to include 
results specific to MSM.  
Topic area Articles needed to address HIV with a focus on prevention. 
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Table 3: Literature Summary 
Author/Location of 
Data Collection 
Description & 
Principle(s) studied 
Type of Research 
(qualitative/quanti
tative) 
If qualitative If quantitative Overall 
Conclusions 
Quality 
(good, 
fair, 
poor) 
   Number of 
participants 
Data 
Collection 
Methods 
Sample 
Size 
Data 
Collection 
Methods 
  
Soto et. al 
15 
(Central America)
 
HIV seroincidence 
and seroprevalence, 
STI prevalence, and 
sociobehavioral 
characteristics among 
MSM in Guatemala, 
El Salvador, 
Honduras, Nicaragua, 
and Panama 
Quantitative   158 Laboratory 
blood draw 
and analysis; 
Risk factor 
questionnaire 
“An ongoing 
HIV epidemic 
involves Central 
American 
MSM… 
prevention must 
incorporate 
acceptable and 
effective sexual 
health services 
including 
condom access 
and promotion” 
Good 
Paz-Bailey et. al 
16 
(Guatemala City) 
Respondent Driven 
Sampling vs. Time 
Location Sampling 
for behavioral 
surveillance 
Quantitative   RDS = 
507 
 
TLS = 
609 
Behavioral 
Questionairre 
“RDS reached a 
more hidden 
subpopulation 
of non-gay 
identifying 
MSM than TLS 
and had a lower 
implementation 
cost” 
 
Good 
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Rhodes et. al
17 
(Guatemala City) 
20 characteristics of 
potentially successful 
programs to reduce 
HIV risk 
Qualitative 87 Focus 
groups 
and in-
depth 
interviews 
  Characteristics 
included 
guidance on 
accessing 
limited 
resources, 
offering 
supportive 
dialogue of 
masculinity, 
sociocultural 
expectations, 
love, intimacy, 
using Mayan 
values and 
images; 
harnessing 
technology; 
increasing 
leadership and 
advocacy skills; 
mobilizing 
social networks 
Fair 
Wheeler et. al
19
  
(Guatemala City) 
Interpersonal 
violence and HIV risk 
in 9 Central 
American citites 
Quantitative   795 RDS surveys MSM who 
experience 
violence are 
more likely to 
engage in 
transactional 
sex, have 
multiple 
partners in the 
last 30 days, 
Fair 
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have sex under 
the influence of 
alcohol. 
Psychological 
and verbal 
violence are 
associated with 
STI symptoms 
and diagnosis. 
Tucker et. al
20 
(Guatemala City) 
MSM and social 
networks 
Qualitative 29 In-depth 
interviews 
  “Gay 
identifying men 
had the largest, 
most supportive 
social networks, 
predominantly 
comprising 
family. For both 
non-gay-
identifying 
MSM and 
transgender 
women, friends 
and sex clients 
provided 
support. HIV 
prevention 
efforts should 
be tailored to 
the specific 
sexual minority 
population and 
engage with 
strong ties”. 
Fair 
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Firestone et. al
21 
(Central America) 
Combination 
prevention therapy 
and HIV risk 
reduction 
Quantitative   750 Survey data “Combination 
prevention is a 
promising 
approach in 
Central 
America, 
requiring 
expansion in 
coverage and 
intensity”. 
Fair 
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Appendix B: In-Depth Interview Guide 
 
Stakeholder perceptions of the facilitators and barriers to implementation of a 
pre-exposure prophylaxis (PrEP) intervention strategy among men who have 
sex with men (MSM) in Guatemala City 
 
Cramer A. McCullen 
The University of North Carolina at Chapel Hill 
 
 
Information Sheet 
 
IRB Status: Exempt   
 
Principal Investigator:    Cramer A. McCullen  
UNC-Chapel Hill Department:   Public Health Leadership Program 
 
Faculty Advisor:    Sue Tolleson-Rinehart PhD 
UNC-Chapel Hill Department:    Assistant Chair for Faculty Development,    
      Department of Pediatrics 
     Co-Associate Director, HC&P MPH, SPH 
     Adjunct Professor of Political Science 
 
       
Advisor Phone #:     (919) 843-9477 
Advisor e-mail:    suetr@unc.edu 
 
Study Contact telephone number:    (704) 277-1409  
 
Study Contact email:  cramer_mccullen@med.unc.edu  
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English Interview Instrument for Key Informants 
Date: _______________        Interviewer ______________________  
    
Start Time: ______________        End Time:____________ 
  
Key informant:  
Organization_______________________________________________________________  
Type of organization: __NGO __Hospital __Public Clinic __Private Clinic __Ministry of Health 
Other:_______________  
Role in the organization:____________________ 
   
Introduction:  
Read this to the participant: “Thank you for talking with me today.  I am part of a team, and we want to learn 
about your knowledge, opinions and attitudes about PrEP. We promise that what you tell us will remain in 
confidence. What you tell us will help us evaluate and improve HIV/AIDS prevention in Guatemala. As we have 
said, everything we talk about here today is confidential. We will record the interview, so we can be sure to 
capture what you tell us accurately.   Once our team has transcribed the information, we will erase the recording.  
You are completely free to answer or not answer any interview question. We thank you for your participation. Do 
you have any questions for me before beginning?” 
Perfect. Let’s begin. 
 *Note the terms or jargon that is used during the interview or that is of interest for the study* 
**Technical Terms: Please define or explain technical terms to the participant** 
 
  
 
 
I. General information  
1. What is your organization’s main focus and what type of people does it serve?  
 
2. What sort of activities does your organization offer for the people it serves?  
 
3. What are your responsibilities in the organization? ___________ 
  
  
  
II. HIV Prevention 
 
Now I would like to get your perspective on the history of the HIV prevention strategies in Guatemala. Tell me about 
the prevention of HIV/AIDS in Guatemala... 
4. In your opinion, what groups are most at risk for HIV infection?  
 
 
5. What HIV prevention services does your organization provide (condoms, HIV prevention 
messaging, counseling, testing, STI management)? 
 
 
6. Have you had experience providing prevention services at high-risk settings such as bars, clubs, 
saunas, etc.?  [IF YES] Can you tell me about those experiences? 
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7. What HIV/AIDS prevention messages do you think are communicated to high risk populations? 
Which are most effective? 
 
 
8. What would you say have been Guatemala’s successes when it comes to preventing HIV? And 
what are the greatest challenges for Guatemala?  
 
9. If they work with MSM: Could you tell me about your work with men who have sex with men? 
 
  
III. Knowledge of PrEP  
  
10. What have you heard about pre-exposure prophylaxis (PrEP) also known as Truvada?  
  
  
  
 
If they do not know about PrEP, explain it with the following paragraph: 
  
PrEP is a promising biomedical intervention against HIV in which HIV-negative people take anti-HIV medications 
(Tenofovir+Emtricitabine) to avoid contracting the infection. PrEP reduces the risk of HIV infection through sexual 
contact in gay and bisexual men, transgender women, and straight men and women as well as in persons that inject 
drugs.  
 
Taking one pill every day in negative people can prevent HIV infection at rates between 96 to 100 percent 
effectiveness by preventing HIV from being able to copy itself in the body after being exposed.  
 
PrEP is not a cure for HIV. It must be taken daily for 7 days before it begins to provide protection against HIV in 
men. PrEP does not prevent other STIs so it is important to use other methods of STI prevention like condoms.  
 
In Guatemala, PrEP costs approximately Q500-600 per month. The most common side effect is stomach upset 
during the first week. In rare cases it can result in kidney damage and renal failure. It is recommended that blood 
tests for kidneys and sexually transmitted infections are performed every 3 to 6 months while taking PrEP.  
  
  
11. Based on what you know about PrEP, what do you think about this new prevention method? 
What do you like about PrEP? What are your concerns? 
 
  
12. What would you need to know about PrEP before you would include it as a prevention tool in 
your work? 
 
13. What do you already have here in Guatemala that would help with implementation of PrEP? 
(institutions, resources, social networks) 
 
 
 
14. And, what are the biggest barriers to implementing PrEP? 
 
 
 
15. What about current Guatemalan policies? Would they help or hurt the implementation of 
PrEP? 
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16. If PrEP were available here in Guatemala, would you provide it to MSM? How? 
 
 
17. What would you or your organization need to do it? 
   
 
 
18. Would some groups of MSM benefit from PrEP more than others? 
 
 
 
IV. Operational aspects of PrEP implementation (Does not apply for entities that do not work with MSM) 
 
19. In the case that PrEP becomes accessible in Guatemala, where should it be made available 
(pharmacy, HIV clinic, community-based organizations)? 
 
 
20. How often should PrEP be provided for pick-up (weekly, monthly)? 
 
 
21. What additional services should be tied to receiving PrEP? 
 
 
22. How often should MSM receive STI screening? Could routine screening be linked to PrEP pick-
up? 
   
 
 
 V. Retention and adherence 
 Now I would like to talk specifically about retention and adherence to PrEP 
  
23. What would be the barriers to retention in a PrEP program among men who have sex with 
men? 
a. Could you tell me an example of why it may be difficult for an MSM to continue with 
their HIV prevention medical care? 
b. Could tell me of an example of an MSM that has been able to follow HIV prevention 
recommendations successfully? Why do you think that that person has been able be 
successful and others have not? 
c. Do you think that MSM are satisfied with the care they receive? 
 
 
 
24. What are the difficulties faced by MSM in regards to adherence to medications? 
a. From what you have observed, what has helped MSM to continue taking their 
medications daily without any lapse? 
 
 
 
 
VI. Support 
25. How can we strengthen your capacity to promote or implement PrEP in Guatemala? 
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VII. Personal Information 
Now can I ask a few questions about you? 
26. What is your age?__________ 
27. What level of schooling did you complete? If you graduated from a particular program what 
was that program? 
 
 
Before we conclude, do you have any questions or comments? Thank you very much for your participation. 
 
 
Guía de entrevista para Informantes Claves 
Fecha:_____________            Encuestador(a)________________________ 
 
Hora de inicio:____________________    Hora al final:_____________________________ 
 
Informante Clave:  
Organización:_______________________________________________________________   
Tipo de organización: __ONG __Hospital __Clínica pública __Clínica privada __Ministerio de Salud   
            Otro:_______________           
Rol en la organización:________________________________________________________ 
 
Lea esto al participante:  “Gracias por hablar conmigo hoy. Soy parte de un equipo y nos gustaría saber de su 
conocimiento, opiniones y actitudes acerca de PrEP. Prometemos que lo que nos digas permanecerá 
confidencial y también nos ayudará a evaluar y mejorar la prevención del VIH/SIDA en Guatemala.  Como 
ya mencionamos todo lo que discutamos será confidencial, grabaremos la entrevista para asegurar que 
captemos precisamente todo lo que nos dirá, y una vez que nuestro equipo haya transcrito la información, la 
grabación será borrada. 
Ud. es completamente libre de responder o no responder a cualquier pregunta en la entrevista, apreciamos su 
participación. Tiene Ud. alguna pregunta para mi antes de que empecemos? 
Perfecto, Vamos a empezar. 
*Anote la terminología o jerga que se usará durante la entrevista o que podría ser de ayuda para el estudio.* 
**Terminología técnica: por favor defina o explique la terminología técnica al participante. ** 
 
 
 
 
 
I. Información General  
 
1. ¿Cuál es el enfoque principal de su organización y a qué tipo de personas sirve?  
 
2. ¿Qué tipo de actividades realiza su organización a las personas a las que atiende? 
 
3. ¿Cuáles son sus responsabilidades en la organización? 
 
 
II. Prevención de VIH  
Ahora nos gustaría saber acerca de la historia y estrategias de prevención de VIH en Guatemala. Díganos 
acerca de prevención de VIH/SIDA en Guatemala…  
 
4. En su opinión, ¿Qué grupos tienen mayor riesgo de contraer VIH? 
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5. ¿Qué tipo de servicios de prevención de VIH provee su organización (condones, mensaje de 
prevención de VIH, consejería, pruebas, manejo de ITS)? 
 
6. ¿Ha tenido Ud. experiencia en proveer servicios de prevención en entornos de alto riesgo de 
contagio de VIH como bares, clubes, saunas, etc.? [Si sí] ¿Podría explicarnos acerca de su 
experiencia? 
 
7. ¿Qué mensajes de prevención de VIH/SIDA piensa Ud. que son comunicados a poblaciones 
de alto riesgo? ¿Cuáles son más eficaces? 
 
8. ¿Cuáles cree Ud. que son los éxitos de prevención de VIH en Guatemala y cuáles son los 
mayores retos? 
 
9. Si trabaja con HSH: ¿Me podría decir sobre su trabajo con HSH? 
 
III. Conocimiento de PrEP 
 
 
10. ¿Qué ha escuchado acerca de la profilaxis pre-exposición (PrEP) más conocido como Truvada? 
 
 
 
 
Si no sabe de PreP, explíque con el siguiente párrafo: 
 
PrEP es una intervención biomédica prometedora contra el VIH en la cual personas que son VIH negativas toman 
medicamentos anti VIH (Tenofovir+Emtricitabina) para evitar contraer la infección. PrEP reduce el riesgo de 
infección de VIH vía contacto sexual en los hombres gay y bisexuales, mujeres transgénero y en hombres y mujeres 
heterosexuales así como en personas que se inyectan drogas. 
Tomando una pastilla cada día en gente negativa puede prevenir la infección de VIH con 96 a 99 por ciento de 
efectividad por prevenir la replicación  de VIH en el cuerpo después de haber sido expuesto.  
 
PrEP no es una cura para el VIH. Tiene que ser tomado diariamente por 7 días antes de que empiece a proveer 
protección contra el VIH en hombres. PrEP no previene otras ITS entonces es importante usar otros métodos de 
prevención de ITS como condones.  
 
En Guatemala, PrEP cuesta aproximadamente Q500-600 cada mes. El efecto secundario más común es malestar de 
estómago durante la primera semana. En raros casos, puede resultar en daño renal y fallo renal. Se recomienda 
pruebas de sangre para monitorear la función de los riñones e infecciones de transmisión sexual las cuales deben 
hacerse cada 3 a 6 meses durante la toma de PrEP.   
 
 
11. Basado en lo que sabe Ud. sobre PrEP, ¿qué piensa Ud. acerca de este nuevo método de prevención? 
¿Qué le gusta de PrEP? ¿Cuáles son sus dudas o preocupaciones de PrEP? 
 
 
12. ¿Qué necesitaría saber Ud. acerca de PrEP antes de incluirlo como una herramienta de prevención 
en su organización? 
 
 
 
13. ¿En Guatemala, que se tiene actualmente que ayudaría en la implementación de PrEP? 
(instituciones, recursos, redes sociales)? 
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14. ¿Y, cuáles son las barreras que se tendrían al implementar PrEP? 
 
 
 
15. ¿Acerca de la política en Guatemala, piensa Ud. que ayudaría o impediría la implementación de 
PrEP? 
 
 
16. Si PrEP estuviese disponible en Guatemala, ¿la proveería Ud. a HSH? ¿Cómo? 
 
 
17. ¿Qué necesitaría Ud. o su organización para poder implementarlo? 
 
 
18. ¿Tendrían algunos sectores o grupos de HSH un mayor beneficio con PrEP que otros? 
 
IV. Aspectos del manejo de la implementación de PrEP (No aplica para entidades que no trabajan con HSH) 
19. ¿En caso de que se implementase PrEP en Guatemala, en dónde cree Ud. que debería de 
estar hecho disponible (farmacia, clínica de VIH, organizaciones a base comunitaria) 
 
20. ¿Con que frecuencia debería ser la obtención de PrEP (semanalmente, mensualmente) 
 
 
21. ¿Qué servicios adicionales debería ser otorgados a las personas cuando reciban PrEP? 
 
22. ¿Con que frecuencia deberían hacerse pruebas de ITS los hombres que tienen sexo con 
hombres al recibir PrEP? ¿Podrían estar vinculadas estas pruebas con la adquisición de 
PrEP? 
 
 
 
V. Retención y adherencia  
Ahora me gustaría hablar específicamente sobre la retención y adherencia a PREP.  
 
23. ¿Cuáles serían las barreras para la retención en un programa de PREP entre hombres que tienen 
sexo con hombres? 
- ¿Podría proveer un ejemplo del por qué  es más difícil para HSH seguir con un control médico de 
prevención de VIH? 
- ¿Podría proveer un ejemplo de un HSH, quien haya podido seguir con las recomendaciones de 
prevención de VIH exitosamente?  ¿Por qué cree que esta persona ha podido ser exitosa y otros no? 
- ¿Piensa que los HSH están satisfechos con la atención que reciben? 
 
 
24. ¿Cuáles son los mayores retos que afrontan a los HSH en cuestión de adherencia a los 
medicamentos? 
- En lo que ha observado, ¿Qué los ha ayudado a los HSH a seguir tomando los medicamentos 
diariamente sin ningún lapso? 
 
IV. Apoyo 
25. ¿Cómo podríamos ayudarle a hacer más fuerte su habilidad de promover o implementar PrEP en 
Guatemala? 
 
 41 
 
IV. Información personal 
Ahora puedo hacerle algunas preguntas sobre Ud? 
26. ¿Cuál es su edad? _________ 
27. ¿Qué nivel escolar se cumplió Ud? Si se graduó de un programa particular, podría 
mencionarlo? 
 
Antes de que concluyamos ¿Tiene Ud. algunas preguntas o comentarios?  Muchas gracias por su participación.  
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Appendix C: Template for Key Informant Interview Analysis 
 
Participant: For-Against-Unsure:  
Context: 
 
Describe any recurring themes: 
 
 
 
 
 
Pro-PrEP reasons: 
 
 
Anti-PrEP reasons: 
PreP Knowledge PrEP Implementation 
Comments: Barriers: Facilitators/Strategies to 
overcome barriers: 
PrEP Management 
Where: 
 
 
Frequency: 
Other services that should be tied to PrEP: 
Retention/Adherence 
How to best support 
implementation or further HIV 
prevention efforts 
Barriers: Facilitators:  
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Appendix D:  List of Key Informants  
 
Name Organization Type  Title 
Aldo Davila Gente Positiva CBO Director 
Johana Ramirez OTRANS CBO Executive Director 
Carlos Valdez LAMBDA CBO Technical Director 
Adriana Carrillo Organización 
Mujeres en 
Superación 
(OMES) 
CBO Executive Director, National 
Coordinator, Legal Representative 
Marco Vinicio Loarca SOMOS CBO Director 
Juan Carlos Hassan GayGuatemala CBO  Director 
Marco Polo Yancor Colectivo Amigos 
contra el SIDA 
CBO Director 
Alma de Leon International 
Treatment 
Preparedness 
Coalition (ITPC) 
International 
HIV/AIDS 
Organization/Funder 
Regional Director 
Dr. Ricardo García UNAIDS International 
HIV/AIDS 
Organization/Funder 
Coordinator 
Dr. Sanny Northbrook CDC Guatemala International 
HIV/AIDS 
Organization/Funder 
HIV Program Director 
Dr. Berta Taracena IntraHealth International 
HIV/AIDS 
Organization/Funder 
Country Representative 
Dr. Karelia Ramos UN Population 
Fund 
International 
HIV/AIDS 
Organization/Funder 
Regional HIV/AIDS Specialist 
Lucrecia Castillo USAID International 
HIV/AIDS 
Organization/Funder 
Regional HIV/AIDS Program 
Coordinator 
Lic. Saira Ortega HIVOS International 
HIV/AIDS 
Organization/Funder 
Local Director 
Dr. Oscar Barreneche and Dr. Pedro 
Avedillo 
Pan American 
Health 
Organization/WHO 
International 
HIV/AIDS 
Organization/Funder 
Country Representative PAHO/WHO 
Guatemala; HIV Treatment and 
Response Specialist PAHO/WHO 
Dr. Carlos Mejía Hospital Roosevelt 
– Infectious 
Disease Clinic 
Medical Clinic Director 
Dr. Eduardo Áraton Asociación de 
Salud Integral 
(ASI) 
Medical Clinic Director 
Yohana García and Dr. Wendolin 
Guerra 
National STI-
HIV/AIDS 
Program (PNS) 
Governmental 
Organization 
Director, HIV Coordinator; PNS 
physician 
Participants ranged in age from 33 to 65 years and in educational level from high school diploma to doctoral 
degrees.  
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Potential Stakeholders not interviewed: 
Organization Type 
REDNADS CBO 
REDMUTRANS CBO 
ODASA CBO 
Fundación Marco Antonio* CBO/Medical Clinic 
SIDA Societat* International HIV/AIDS Organization/Funder 
AIDS Healthcare Foundation (AHF)* International HIV/AIDS Organization/Funder 
Pan American Social Marketing Organization 
(PASMO)* 
International HIV/AIDS Organization/Funder 
USAID – Program for Strengthening the Central 
American Response to HIV/AIDS (PASCA)* 
International HIV/AIDS Organization/Funder 
Guatemala Social Security Institute (IGGS)* Governmental Organization 
 *Organizations contacted but which did not respond for interview 
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Appendix E: Transcriptionist Letter of Ethical Commitment 
 
 
CARTA DE COMPROMISO ÉTICO 
 
 
Yo _______________________________________, mayor de edad, con documento legal de 
identificación tipo ____________________ (DPI, pasaporte, etc.) No.______________________________, por 
este medio dejo constancia que en mi carácter de ___________ y como parte del equipo de campo del 
estudio: “Stakeholder perceptions of the facilitators and barriers to implementation of a pre-exposure 
prophylaxis (PrEP) intervention strategy among men who have sex with men (MSM) in Guatemala City”, 
me comprometo a respetar y hacer cumplir las siguientes normas y lineamientos éticos: 
 
 
 
1. Asegurar y vigilar el cumplimiento de los aspectos éticos mi trabajo hacia las poblaciones tales 
como: privacidad, confidencialidad, anonimato  
 
2. Resguardar de manera segura y confidencial la información, papelería, bases de datos, audios y 
equipo relacionado con las funciones que desempeño. 
 
3. Respetar las opiniones y no emitir juicios de valores morales o religiosos durante el proceso de 
transcripción, en particular sobre temas de orientación y comportamientos sexuales y del estatus de 
VIH de las personas entrevistadas o de otras referidas en los audios. 
 
4. No divulgar información de las entrevistas ni crear copias de los audios de entrevista  
 
5. Mantener un comportamiento de respeto al contenido de cada entrevista. 
 
6. Mantener, entre los miembros de los diferentes equipos, una relación de respeto y profesionalismo 
a fin de desempeñarse en un ambiente armonioso y adecuado.  
 
 
Estoy consciente que de faltar a cualquiera de los aspectos antes descritos, el equipo del UNC 
procederá según las normas y procedimiento establecidos por las autoridades del país y de UNC.  
 
Para los fines que a los interesados convenga, se firma la presente carta de compromiso ético en la 
ciudad de _________________ a los ____ días del mes de ________________ del año _______. 
 
 
Nombre del/la transcriptor/a: ____________________________________________________ 
 
 
 
Firma del/la transcriptor/a: ____________________________________________________ 
 
 
  
Nombre del investigador principal:____________________________________ 
 
 
